EMA positive opinion for ViiV’s cabotegravir
The drug is an injectable or tablet specifically developed for HIV prevention among certain individuals
Read Moreby John Pinching | Jul 24, 2023 | News | 0
The drug is an injectable or tablet specifically developed for HIV prevention among certain individuals
Read Moreby Selina McKee | Jul 3, 2020 | News | 0
60% of heavily treatment-experienced patients achieved undetectable viral load after taking the drug
Read Moreby Selina McKee | Jul 1, 2020 | News | 0
ViiV received more than 400 applications from across the world, with eligible submissions coming from Africa, Asia, Europe, South America and the US
Read Moreby Selina McKee | Jun 15, 2020 | News | 0
The formulation and an expanded indication for Tivicay tablets are currently under review in Europe
Read Moreby Selina McKee | May 18, 2020 | News | 0
ViiV said cabotegravir was found to be 69% more effective at preventing HIV acquisition than daily oral PrEP with emtricitabine/tenofovir disoproxil (FTC/TDF)
Read Moreby Selina McKee | Apr 28, 2020 | News | 0
It is hoped that the move will help address some of the questions being asked by the HIV community
Read Moreby Anna Smith | Mar 23, 2020 | News | 0
Canada has also approved Vocabria to be used for short time periods in conjunction with the drug.
Read Moreby Selina McKee | Dec 23, 2019 | News | 0
US regulators have declined ViiV Healthcare’s application to market an investigational long-acting regimen for the treatment of HIV
Read Moreby Selina McKee | Dec 16, 2019 | News | 0
The company is seeking approval to market the formulation for children with HIV
Read Moreby Selina McKee | Dec 6, 2019 | News | 0
The treatment could offer a new option for patients unable to reach viral supression
Read Moreby Anna Smith | Aug 22, 2019 | News | 0
The drug could now be administered every eight weeks compared to every four.
Read Moreby Selina McKee | Jul 3, 2019 | News | 0
Availability of the two-drug regimen is considered a significant development for people with the condition
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
